CircRNA Larp4b/miR-298-5p/Mef2c Regulates Cardiac Hypertrophy Induced by Angiotensin II

Abstract

Cardiac hypertrophy (CH) is an early marker in the clinical course of heart failure. Circular RNAs (circRNAs) play important roles in human disease. However, the role of circ_Larp4b in myocardial hypertrophy has not been studied. Angiotensin II (Ang II) treated HL-1 cells to induce a CH cell model. Quantitative real-time polymerase chain reaction was used to detect the expression of circ_Larp4b, microRNA-298-5p, and myocyte enhancer factor 2 (Mef2c). Western blot detected the protein level of alpha-actinin-2 (ACTN2), beta-myosin heavy chain (β-MHC), atrial natriuretic peptide (ANP), and Mef2c. The relationship between miR-298-5p and circ_Larp4b or Mef2c was verified by dual-luciferase reporter assay and RNA pull-down assay. Circ_Larp4b and Mef2c were upregulated in HL-1 cells treated with Ang II. Moreover, circ_Larp4b down-regulation regulated the progress of CH induced by Ang II. MiR-298-5p was a target of circ_Larp4b, and Mef2c was a target of miR-298-5p. Overexpressed Mef2c reversed the cell size inhibited by miR-298-5p in Ang II-induced HL-1 cells. Circ_Larp4b regulated CH progress by regulating miR-298-5p/Mef2c axis.

Key words

circ_larp4b - mir-298-5p - cardiac hypertrophy - mef2c - skeletal muscle - regeneration - exercise physiology - oxidative stress - myosin

Publication History

Received: 08 November 2022

Accepted: 22 August 2023

Article published online:
13 November 2023

• References

• 1 Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79
• 2 Dorn GW, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003; 92: 1171-1175
• 3 MacDonald MR, Petrie MC, Hawkins NM. et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-1240
• 4 Tham YK, Bernardo BC, Ooi JY. et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 2015; 89: 1401-1438
• 5 Altesha MA, Ni T, Khan A. et al. Circular RNA in cardiovascular disease. J Cell Physiol 2019; 234: 5588-5600
• 6 Bernardo BC, Ooi JY, Lin RC. et al. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem 2015; 7: 1771-1792
• 7 Kristensen LS, Andersen MS, Stagsted LVW. et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet 2019; 20: 675-691
• 8 Verduci L, Strano S, Yarden Y. et al. The circRNA-microRNA code: emerging implications for cancer diagnosis and treatment. Mol Oncol 2019; 13: 669-680
• 9 Xu L, Li W, Shi Q. et al. MicroRNA‑936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway. Oncol Rep 2020; 43: 635-645
• 10 Ni H, Li W, Zhuge Y. et al. Inhibition of circHIPK3 prevents angiotensin II-induced cardiac fibrosis by sponging miR-29b-3p. Int J Cardiol 2019; 292: 188-196
• 11 Wu N, Xu J, Du WW. et al. YAP Circular RNA, circYap, attenuates cardiac fibrosis via binding with tropomyosin-4 and gamma-actin decreasing actin polymerization. Mol Ther 2021; 29: 1138-1150
• 12 Li H, Xu JD, Fang XH. et al. Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4. Cardiovasc Res 2020; 116: 1323-1334
• 13 Ucar A, Gupta SK, Fiedler J. et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012; 3: 1078
• 14 Huang ZP, Chen J, Seok HY. et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res 2013; 112: 1234-1243
• 15 Li Z, Song Y, Liu L. et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ 2017; 24: 1205-1213
• 16 Kesherwani V, Nandi SS, Sharawat SK. et al. Hydrogen sulfide mitigates homocysteine-mediated pathological remodeling by inducing miR-133a in cardiomyocytes. Mol Cell Biochem 2015; 404: 241-250
• 17 Stegeman R, Paauw ND, de Graaf R. et al. The etiology of cardiac hypertrophy in infants. Sci Rep 2021; 11: 10626
• 18 Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423
• 19 Singh MV, Cicha MZ, Meyerholz DK. et al. Dual ACTIVATION of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension 2015; 66: 647-656
• 20 Kobara M, Toba H, Nakata T. Roles of autophagy in angiotensin II-induced cardiomyocyte apoptosis. Clin Exp Pharmacol Physiol 2022; 49: 1342-1351
• 21 Ye S, Luo W, Khan ZA. et al. Celastrol attenuates angiotensin II-induced cardiac remodeling by targeting STAT3. Circ Res 2020; 126: 1007-1023
• 22 Ju J, Song YN, Chen XZ. et al. circRNA is a potential target for cardiovascular diseases treatment. Mol Cell Biochem 2022; 477: 417-430
• 23 Du WW, Yang W, Chen Y. et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J 2017; 38: 1402-1412
• 24 Zhong Y, Du Y, Yang X. et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer 2018; 17: 79
• 25 Wehbe N, Nasser SA, Pintus G. et al. MicroRNAs in cardiac hypertrophy. Int J Mol Sci 2019; 20
• 26 de Oliveira Silva T, Lino CA, Miranda JB. et al. The miRNA-143-3p-Sox6-Myh7 pathway is altered in obesogenic diet-induced cardiac hypertrophy. Exp Physiol 2022; 107: 892-905
• 27 Li J, Sha Z, Zhu X. et al. Targeting miR-30d reverses pathological cardiac hypertrophy. EBioMedicine 2022; 81: 104108
• 28 Wallach T, Mossmann ZJ, Szczepek M. et al. MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous toll-like receptor 7/8 ligands that contribute to neurodegeneration. Mol Neurodegener 2021; 16: 80
• 29 Wei X, Xu S, Chen L. LncRNA Neat1/miR-298-5p/Srpk1 Contributes to Sevoflurane-Induced Neurotoxicity. Neurochem Res 2021; 46: 3356-3364
• 30 Borlot F, Whitney R, Cohn RD. et al. MEF2C-related epilepsy: Delineating the phenotypic spectrum from a novel mutation and literature review. Seizure 2019; 67: 86-90
• 31 Bao Z, Hua L, Ye Y. et al. MEF2C silencing downregulates NF2 and E-cadherin and enhances erastin-induced ferroptosis in meningioma. Neuro Oncol 2021; 23: 2014-2027